Tsukasa Kuwana

Dr. Tsukasa Kuwana

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
ASAtsunori Sugita
Atsunori Sugita
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
ASAtsushi Sakurai
Atsushi Sakurai
NCNobutaka Chiba
Nobutaka Chiba
JYJunko Yamaguchi
Junko Yamaguchi
SHSatoshi Hori
Satoshi Hori
Ischemia/reperfusion injury (I/R) is an important pathophysiology of post-cardiac arrest syndrome (PCAS) against multiple organ dysfunction and mortality. The inflammatory response in PCAS causes systemic I/R. The purpose of this study was to demonstrate the pathophysiology of systemic I/R for secondary brain damage using the biomarkers high-mobility group box 1 (HMGB1), neuron-specific enolase (NSE), and interleukin-6 (IL-6). This study was designed as a single-institution prospective observational study. Subjects were observed for 90 days, and neurological outcome was classified according to the Glasgow-Pittsburgh Cerebral Performance Categories Scale (CPC). Serum HMGB1, NSE, and IL-6 were evaluated for variability, correlation with each biomarker, or the Sequential Organ Function Assessment (SOFA) score and CPC at return of spontaneous circulation at 0, 24, 48, and 168 h. A total of 128 patients were enrolled in this study. Initial HMGB1 correlated with CPC (ρ = 0.27, p = 0.036) and SOFA score (ρ = 0.33, p < 0.001). The early phase of HMGB1 (0–24 h), all phases of IL-6, and the delayed phase of NSE (24–168 h) manifested poor neurological outcome. HMGB1 showed a significant correlation with NSE (ρ = 0.29, p = 0.002 at 0 h; ρ = 0.42, p < 0.001 at 24 h) and IL-6 (ρ = 0.36, p < 0.001 at 24 h). Serum HMGB1 for first 24 h after cardiac arrest was significantly correlated with SOFA score, NSE, and IL-6. This result suggests that systemic I/R may contribute to secondary brain aggravation. It is expected that research on HMGB1 focused on systemic I/R will help prevent aggravating neurological outcomes.

6 October 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JKJun Kamei
Jun Kamei
MKMasafumi Kanamoto
Masafumi Kanamoto
YIYutaka Igarashi
Yutaka Igarashi
KSKodai Suzuki
Kodai Suzuki
KFKensuke Fujita
Kensuke Fujita
JGJ-STAD (Japan Sepsis Treatment and Diagnosis) Study Group
J-STAD (Japan Sepsis Treatment and Diagnosis) Study Group
Sepsis leads to organ dysfunction. Acute kidney injury, a common type of organ dysfunction, is associated with a high mortality rate in patients with sepsis. Kidney replacement therapy can correct the metabolic, electrolyte, and fluid imbalances caused by acute kidney injury. While this therapy can improve outcomes, evidence of its beneficial effects is lacking. Herein, we review the indications for blood purification therapy, including kidney replacement therapy, and the current knowledge regarding acute kidney injury in terms of renal and non-renal indications. While renal indications have been well-documented, indications for blood purification therapy in sepsis (non-renal indications) remain controversial. Excessive inflammation is an important factor in the development of sepsis; blood purification therapy has been shown to reduce inflammatory mediators and improve hemodynamic instability. Given the pathophysiology of sepsis, blood purification therapy may decrease mortality rates in these patients. Further trials are needed in order to establish the effectiveness of blood purification therapy for sepsis.

1 April 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
MHMarina Hirabayashi
Marina Hirabayashi
SIShingo Ihara
Shingo Ihara
NSNami Sawada
Nami Sawada
JYJunko Yamaguchi
Junko Yamaguchi
Hypercytokinemia induced by coronavirus disease-19 (COVID-19) is associated with severe pulmonary involvement, which may lead to respiratory failure. These conditions play an important role in the worsening of clinical symptoms in patients with severe COVID-19. There is no established treatment for hypercytokinemia. We report on two patients whose clinical symptoms improved after direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP), following the administration of the anti-inflammatory agent tocilizumab. Case A was a 70-year-old man diagnosed with COVID-19 pneumonia. Despite treatment with ciclesonide and favipiravir, supplemental oxygen was administered due to the worsening of dyspnea with tachypnea. Although tocilizumab was started on day 6, the patient deteriorated into deoxygenation, presenting with the PaO2/FIO2 (P/F) ratio of 92. On days 8 and 10, the patient received PMX-DHP therapy. On day 11, his dyspnea improved. On day 13, his P/F ratio began to improve, and oxygen therapy was discontinued on day 18. The patient recovered without requiring mechanical ventilation. Case B was a 70-year-old man diagnosed with COVID-19 pneumonia and treated with favipiravir, starting on day 0. Despite starting ciclesonide inhalation and tocilizumab on day 2, his P/F ratio was 53. On day 5, he received PMX-DHP therapy. On day 6, his dyspnea improved, as did his P/F ratio, reaching 81 on day 8. Finally, his clinical symptoms resolved, and he was discharged from the intensive care unit without requiring mechanical ventilation. These cases indicate that PMX-DHP therapy might be a suitable treatment option for dyspnea and deoxygenation in COVID-19 pneumonia, especially in cases where an anti-inflammatory agent, such as tocilizumab, has failed to achieve the desired effect.

24 August 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
SIShingo Ihara
Shingo Ihara
NSNami Sawada
Nami Sawada
THToru Hosokawa
Toru Hosokawa
JYJunko Yamaguchi
Junko Yamaguchi
Purpose: The characteristics of patients with severe COVID-19 pneumonia who underwent direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP), in addition to steroids and immunomodulators, remain unclear. Patients and Methods: We conducted a retrospective observational study on 31 patients with severe COVID-19 pneumonia treated with PMX-DHP in an intensive care unit (ICU) from December 2020 to September 2021. Results: Outcomes 28 days after admission to the ICU were 20 in the survival group and 11 in the death group. Parameters significantly different between the survival and death group before PMX-DHP were percentage of invasive mechanical ventilation (25% vs 72.7%, P = 0.0209), PaO2/FIO2 (P/F) ratio (104.5 vs 75, P = 0.0317), and sequential organ failure assessment (SOFA) score (2 vs 3, P = 0.0356). Invasive mechanical ventilation avoidance rate was significantly different between the survival (100%) and death group (0%) (P = 0.0012). P/F ratio, respiratory ratio (RR), and lymphocyte counts improved significantly after PMX-DHP for all patients. The lymphocyte counts changed significantly in the survival (P < 0.0001), but not the death group (P = 0.7927). Conclusion: PMX-DHP, in addition to steroids and immunomodulators, may improve oxygenation and alleviate tachypnea by modulating the lymphocyte numbers and levels of various mediator against severe COVID-19 pneumonia. It may be better to perform PMX-DHP before multi organ dysfunction and lung injury has progressed. Furthermore, the early increase in lymphocyte counts after PMX-DHP might be an indicate a positive outcome.

24 February 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
TKTsukasa Kuwana
Tsukasa Kuwana
Kosaku KinoshitaKosaku Kinoshita
Kosaku Kinoshita
MMMinori Mizuochi
Minori Mizuochi
JSJun Sato
Jun Sato
NCNobutaka Chiba
Nobutaka Chiba
ITImai Toru
Imai Toru
Dextromethorphan (DXM) is used to treat colds and coughs; however, it can cause central nervous system symptoms, such as severe serotonin syndrome (SS). To our knowledge, there is no specific treatment for severe DXM poisoning, and there are no reports on the clinical use of intravenous lipid emulsion (ILE) for its treatment. Herein, we report a case of severe DXM poisoning with SS that was successfully treated with ILE. An older adolescent male visited the emergency department 1 h after ingesting 4500 mg of DXM orally. Physical examination revealed generalized convulsions, muscle rigidity, mydriasis (8.0/8.0 mm), and flushed skin, with a Glasgow Coma Scale score of 8 (E3V1M4). Severe DXM poisoning with SS was diagnosed. The patient was intubated and administered midazolam for continuous convulsions and SS. Activated charcoal was also administered, and body surface cooling was performed. After an 11 h intensive care unit admission, SS with mydriasis (6.0/6.0 mm) did not improve. Subsequently, 1100 mL of 20% soybean oil was injected as an ILE. Mydriasis improved (3.5/3.5 mm) 30 min after ILE administration; simultaneously, blood DXM concentration rapidly increased approximately two-fold. After discontinuing midazolam, the patient’s consciousness signs improved, and he was weaned off the ventilator. SS was cured with no recurrence of convulsions. In cases of DXM poisoning with severe central nervous system disorders, such as SS, ILE treatment can potentially be an effective therapeutic option. For oral overdose cases, where the drug may remain in the intestinal tract, measures such as administering activated charcoal should be taken before administering ILE.

1 June 2025 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
KHKoichiro Hori
Koichiro Hori
RARiku Arai
Riku Arai
TKTsukasa Kuwana
Tsukasa Kuwana
AKAgune Kohei
Agune Kohei
KKkeisuke kojima
keisuke kojima
YOYasuo Okumura
Yasuo Okumura
Background: Haemophilus influenzae (H. influenzae) is a common commensal bacterium of the upper respiratory tract, with nontypeable H. influenzae (NTHi) increasingly recognized as a cause of invasive infections. Although purulent pericarditis itself is a rare but life-threatening condition, cases caused by NTHi are exceptionally rare, with only a few reported worldwide. Case Presentation: We report a case of a 63-year-old immunocompromised woman with a history of hematologic malignancy and prior Hib vaccination who developed NTHi-associated purulent pericarditis and septic shock. She initially presented with dyspnea and fever and was found to have cardiac tamponade requiring emergency pericardiocentesis. Despite initial improvement, she deteriorated with septic shock and severe pneumonia, necessitating mechanical ventilation. Blood and pericardial fluid cultures confirmed NTHi infection. Given persistent systemic inflammation and high risk of constrictive pericarditis, she underwent surgical pericardiectomy, which led to clinical recovery and successful discharge. Discussion: NTHi as a causative agent is exceedingly uncommon, with very few cases reported in the literature. The increasing incidence of invasive NTHi infections highlights the need for greater clinical awareness, particularly in immunocompromised patients. Pyogenic pericarditis has a high mortality rate, requiring prompt diagnosis and intervention. Our case supports prior observations that H. influenzae-associated pericarditis may be unresponsive to drainage alone, with pericardiectomy playing a critical role in infection control and prevention of constrictive pericarditis. This case underscores the importance of early recognition of invasive NTHi infections and highlights the potential necessity of early surgical intervention in H. influenzae-associated purulent pericarditis. Clinicians should consider H. influenzae as a causative agent in bacterial pericarditis and recognize the need for early, aggressive management to optimize patient outcomes.